Commentary: Zaltrapped –Sanofi’s colder calculations of a drug’s worth
This article was originally published in Scrip
Executive Summary
Sanofi’s decision to halve the net price of its newly approved VEGF inhibitor Zaltrap for may have less to do with public condemnation by individual high profile clinical researchers and much more to with a localized outbreak of sensitive urgent commercial knowledge syndrome.